@article{55d3e945479a4e20b313a075fe6a7528,
title = "A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development",
abstract = "YTB323, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, retains T-cell stemness after a manufacturing process time of less than 2 days and demonstrates clinical antitumor activity at significantly lower doses than traditionally manufactured CAR T cells. Traditional CAR T-cell manufacturing requires extended ex vivo cell culture, reducing naive and stem cell memory T-cell populations and diminishing antitumor activity. YTB323, which expresses the same validated CAR as tisagenlecleucel, can be manufactured in <2 days while retaining T-cell stemness and enhancing clinical activity at a 25-fold lower dose.",
author = "Michael Dickinson and Pere Barba and Ulrich J{\"a}ger and Shah, {Nirav N.} and Didier Blaise and {Briones Meijide}, Javier and Leyla Shune and Nicolas Boissel and Attilio Bondanza and Luisa Mariconti and Anne-Laure Marchal and Quinn, {David S.} and Jennifer Yang and Andrew Price and Akash Sohoni and Treanor, {Louise M.} and Orlando, {Elena J.} and Jennifer Mataraza and Jaclyn Davis and Darlene Lu and Xu Zhu and Boris Engels and {Moutouh-de Parseval}, Laure and Brogdon, {Jennifer L.} and Michele Moschetta and Flinn, {Ian W.}",
year = "2023",
doi = "10.1158/2159-8290.CD-22-1276",
language = "English",
volume = "13",
pages = "1982--1997",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
}